FDA grants rare paediatric designation to Vanda’s CMT2S therapy
The status was granted by the FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics.
Drug Development
Biocytogen and Whitehawk partner to develop ADCs
Vertex signs agreement to acquire Crinetics for $10bn
EC approves AbbVie’s Tepkinly combination for follicular lymphoma
Novartis to acquire Myricx Bio in up to $1.5bn deal
Besins Healthcare boosts drug delivery portfolio with UniD deal
SK bioscience to lead Gates Foundation-funded ROTOR project
European Commission approves Novartis’ Itvisma to treat SMA
